Cellebrite: 3 Key Takeaways for Long-Term Investors
Cellebrite (CLBT) Stock Could Be Undervalued As Cash Flow Builds
Cellebrite DI (CLBT) Slides On Guidance Reset As Undervalued Narrative Faces A Test
Earnings Beat May Recast The Case For Cellebrite Stock
JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $15
Cellebrite DI Ltd. Q3 2026 Earnings Call Summary
Cellebrite (CLBT) Q3 2026 Earnings Call Transcript
Cellebrite DI Q3 Earnings Call Highlights
Cellebrite DI Ltd. (CLBT) Q3 2026 Earnings Call Transcript
Cellebrite DI Ltd (NASDAQ:CLBT) Q3 Results: Revenue In Line, EPS Beat Supports Premarket Gain
Cellebrite Reports Third-Quarter 2026 Results
Cellebrite DI Lowers FY2026 Sales Guidance from $555.000M-$561.000M to $553.000M-$558.000M vs $556.733M Est
Cellebrite DI Q3 Adj. EPS $0.17 Beats $0.16 Estimate, Sales $149.022M Beat $145.923M Estimate
Cellebrite DI Sees Q4 Sales $145.000M-$150.000M vs $151.451M Est
Cellebrite to Report Third-Quarter 2026 Financial Results on November 12, 2026
Genesis Momentum Powers Cellebrite's Autumn Release: More Evidence, Deeper Insight, Broader Access for Investigations
Cellebrite's 2026 Outlook: Subscription Pivot Weighs on the Stock Today, Helps Lead a Future Rebound
Cellebrite Calls for 2027 JUSTYS Nominees, Premier Event Highlights Unsung Heroes Who Keep the World Safe
Is Cellebrite DI (CLBT) A Bargain On Its Subscription Growth Narrative?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.